Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.950-1.050 for the period, compared to the consensus EPS estimate of 0.950. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Amneal Pharmaceuticals also updated its Q1 2026 guidance to 0.270-0.270 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on AMRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Truist Financial upped their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, UBS Group began coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $12.65 on Friday. The company’s 50-day moving average is $13.09 and its 200-day moving average is $12.53. The stock has a market capitalization of $3.98 billion, a PE ratio of 33.29 and a beta of 1.32. Amneal Pharmaceuticals has a 1 year low of $7.02 and a 1 year high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Wednesday, April 22nd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.11. Amneal Pharmaceuticals had a negative return on equity of 276.67% and a net margin of 4.53%.The business had revenue of $723.00 million during the quarter, compared to analyst estimates of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. On average, analysts anticipate that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Announced agreement to acquire Kashiv BioSciences to build a vertically integrated biosimilars platform, which materially expands Amneal’s addressable market and long‑term growth runway. Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals
• Positive Sentiment: Posted strong preliminary Q1 results and raised FY2026 standalone EPS guidance (now 0.95–1.05), signaling better near‑term operating performance than Street expectations. AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
• Positive Sentiment: Reported Q1 revenue of ~$723M and EPS that topped consensus (reported EPS ~ $0.26–0.27 vs. analyst estimates ~ $0.15–0.17), supporting the raised outlook. Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: Coverage shows different deal valuations (reports range from ~$750M to up to $1.1B depending on contingent consideration and structure); agreement is subject to shareholder and regulatory approvals—timing and final consideration remain uncertain. Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
• Neutral Sentiment: Analyst/fundamental writeups dig into quarter‑over‑year metrics and mix shifts — useful for modeling near‑term margins but not immediate market movers absent surprises. Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• Negative Sentiment: Deal funding (cash + stock, contingent payments) and Amneal’s low net margin and sharply negative ROE raise questions about near‑term dilution, leverage and execution risk as the company integrates Kashiv. Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of large investors have recently modified their holdings of AMRX. Kemnay Advisory Services Inc. bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $26,000. Federated Hermes Inc. lifted its stake in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares in the last quarter. Comerica Bank lifted its stake in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares in the last quarter. Transamerica Financial Advisors LLC grew its holdings in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Amneal Pharmaceuticals during the third quarter valued at about $42,000. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.